The Effect of Connected “Smart” Inhalers on Medication Adherence

Caroline Zabczyk and John D. Blakey

Asthma and chronic obstructive pulmonary disease (COPD) are highly prevalent worldwide, and major sources of morbidity. Key barriers to reduce the harm from these conditions are the widespread and related issues of low use of prescribed inhaled therapy, use of medicines differently from that prescribed, suboptimal inhaler technique, and lack of adherence are the action plans. Connected smart inhalers show great potential to improve these issues, and thus outcomes from airways disease. In this mini-review, we considered the published evidence that the use of smart inhalers leads to more doses of preventative treatment being taken on time and with appropriate techniques. We found multiple trials across a variety of settings and age groups where smart inhalers were used with audio-visual reminders and healthcare professional feedback, which substantially improved the number of doses of preventative treatment taken. Trial evidence also supports the use of feedback from smart inhalers in improving true concordance (doses taken correctly and on time), though only for a single type of smart device. The relative lack of study is in contrast with the potential impact of smart inhalers. Major research questions remain unresolved, as who might fund future large-scale studies, how guideline committees may consider them, and how to implement effective solutions.

Keywords: asthma, chronic obstructive pulmonary disease, inhaled administration, adherence, digital technology, smart inhalers

INTRODUCTION

Obstructive airways diseases affect people of all ages worldwide. These conditions are highly prevalent, for example in Australia, more than 10% of the population have asthma, and ~5% aged 45 and over have chronic obstructive airways disease (COPD) (1, 2). On a larger scale, asthma was estimated to affect 262 million people worldwide and caused 461,000 deaths in 2019 (3). COPD is the third leading cause of death worldwide, with 3.23 million deaths in 2019 (4). Best practice treatment guidelines for asthma and COPD are well-established and accepted [e.g., (5)]. Despite the multitude of clinically effective treatment options available, there is persistence in poor outcomes for patients with asthma and COPD. Unscheduled healthcare visits and impaired quality of life remain common (6, 7). These issues lead to tremendous direct healthcare costs and indirect costs of a similar magnitude (8, 9). According to the AIHW Disease Expenditure Database, in 2015–2016, asthma cost the Australian Health system an estimated $770 million, and COPD cost US$977 million (1, 2).

Adherence

As with other chronic diseases, suboptimal adherence to therapy is a key driver of the observed high morbidity, mortality, healthcare expenditure, and decreased quality of life in patients with
asthma and COPD (10, 11). Adherence is defined by the WHO as “the degree to which the person’s behaviour corresponds with the agreed recommendations from a health care provider.”

Non-adherence can be variously classified for clinical and research purposes (12). The main categories of adherence issues are shown in Figure 1. It has long been clear that a step change is required in all these adherence categories in relation to inhaled medication for airways disease. A minority of individuals possess sufficient medication to take their inhalers as prescribed, with a variety of drivers for this (13). Those that collect their inhalers often have suboptimal inhaler techniques, with common types of errors being associated with adverse clinical outcomes. The proportion of appropriately taken doses in the overall number of inhalations may be referred to as competence (14). Additionally, inhalers are commonly discarded before they are empty (15). No intervention has been shown to improve all aspects of adherence to inhaled therapy at scale.

Given the burden and cost of airways diseases and the relative lack of progress with inhaler concordance, the emergence of “smart” connected inhalers is a potentially crucial step forward in this space.

**Smart Inhalers and Their Potential**

The term “smart inhaler” is not subject to a universally agreed definition. As a working description, we consider them to be inhaler-based electronic monitoring systems to record drug usage, with or without an assessment of the technique of device use. This practical characterisation does not include nebulisers, or software systems that purely use a separate electronic device e.g., image recognition technology on phones or tablets. The majority of smart inhalers deployed over the past decade have been of the format of a standard inhaler with an additional electronic fitment. Examples of this are demonstrated in Figure 2.

Electronic monitoring of inhaler adherence has been available for more than 30 years, with the Nebuliser Chronolog (16) being the first device in common academic use. However, it is only in the past 10 years or so that the relevant electronics have become sufficiently small, reliable, and affordable to realise the potential for widespread deployment. These advances have been accompanied by improvement in wireless technologies and mobile computing that allow information to be rapidly transferred from the inhaler, remotely analysed, on a personal device, and presented to the user in a meaningful and graphically pleasing manner.

---

**FIGURE 1** Adherence and competence with respect to inhaler use. Green columns represent inhaler doses correctly administered by the patient, and red columns represent missed or incorrectly administered doses due to poor inhaler technique, insufficient resources or non-adherence.
The technological capabilities available currently include recording when an inhaler was used, reminding patients of their next dose, analysis of technique through measurement of inspiratory flow rate, and feedback on technique and timing of inhaler use. The data generated by these devices can also be transferred securely to a healthcare professional to provide a “real world” perspective on adherence and competence to medication of each patient (17). This adds further layers of potential benefit in terms of adherence: the user knows their activities are being recorded and so may be more concordant, and the healthcare practitioner may tailor their consultations to the individual patient with these data to promote regular appropriate use or recognise and praise concordance. Furthermore, the concordance amongst each doctor or team’s patients is also known, allowing peer benchmarking.

**Barriers to the Implementation of Smart Inhalers**

There is resistance to change the established patterns of working in all areas of medicine even when well-established guidance is available (18). There are additional issues in relation to smart inhalers are around:

- the acceptability of this monitoring to patients who may feel their autonomy and privacy is compromised
- uncertainty around clinical responsibility for reviewing and acting on these new large-scale continuous data streams
- lack of clarity over who will bear the cost of new technologies.

The majority of perceived and actual barriers can be overcome by high-quality research publications demonstrating the efficacy and effectiveness of “smart inhalers” in improving adherence, disease monitoring, and ultimately health outcomes for patients with asthma and COPD. Once effectiveness is established, a clear framework can be constructed to integrate their use into clinical practise guidelines. This review, therefore, aims to summarise the available evidence that the use of smart inhalers increases true medication adherence.

**REVIEW FRAMEWORK**

This mini-review considers the following potential opportunities for connected smart inhalers to improve adherence:

1. Increase the number of doses of preventer taken (total doses)
2. Increase the number of doses of preventer taken as prescribed (doses taken on time)
3. Increase the number of doses of preventer taken appropriately (doses taken with good technique)
4. Facilitation of appropriate escalation to next step in asthma or COPD action plan (minimise harm if it is occurring).

The review is of a narrative type rather than a systematic evaluation given the paucity of trial evidence and the heterogeneity in studies that have been undertaken.

**SMART INHALERS AND CONCORDANCE WITH REGULAR INHALED THERAPY**

**Do Smart Inhalers Increase Medicine Use?**

Studies in this area have considered the value of audio-visual reminder feedback (AVRF) from smart inhalers, and the provision of healthcare professional feedback in the clinic, to promote adherence.

In 2007, Charles et al. (19) published the results of a study that had enrolled 110 individuals with asthma aged 12–65 into a randomised trial of AVRF. All participants received a smart inhaler, but in the control arm, it was solely used to capture the primary outcome of medicine adherence. There was a significantly greater use of medicine in the intervention group than the control group during the second of 12 weeks of follow up (88% of total intended doses vs. 66%). The overall high-rate of concordance may reflect participants being recruited from a database of research volunteers. A subsequent larger randomised trial replicated these findings in a different setting (20). Similar to the Charles study, Chan et al. provided smart inhalers to participants but only the intervention arm had AVRF activated. Importantly, this study recruited only children and adolescents from those attending acutely with a suspected exacerbation. Over the 6-month follow-up, adherence was significantly higher in the group receiving reminders (median 84% of total intended doses) than those who did not (30%).

The effect of healthcare professionals feeding back concordance information from smart inhalers was investigated by Burgess et al. (21) in individuals attending a paediatric respiratory clinic. In this randomised pilot study (total n = 26), medication adherence was higher in those children receiving feedback (79%) than those that did not (58%) over 4 months.

Combining the potential of AVRF and feedback from healthcare professionals, the "STudy of Asthma Adherence Reminders" (STAAR) (22) enrolled children with uncontrolled asthma (Asthma Control Questionnaire >1.5). All children received a smart inhaler, but the intervention group was told their data would be downloaded and reviewed at the clinic, and their devices also provided audible reminders of doses due. There was a substantial difference in adherence, albeit this was a secondary outcome: 70% of total intended doses were dispensed in the intervention group vs. 49% in the control group. These results should be interpreted in the context of 50% of the intervention group reporting their devices to be broken, compared to 19% in
the control arm. This phenomenon has been alluded to but not so clearly demonstrated in other studies.

Complementing and extending these secondary care paediatric results, Foster et al. (23) undertook a cluster randomised trial amongst adolescents and adults in primary care. Sixty general practitioners (GPs) were randomly selected to provide either inhaler reminders and feedback, personalised adherence discussions, both of these interventions, or usual care. The 40 GPs completed the study enrolling 143 patients on LABA-ICS with suboptimal asthma control (Asthma Control Test < 19). Those individuals in the AVRT groups took around twice as great a proportion of the prescribed doses of preventer at 6 months of follow-up (60 vs. 29%).

Therefore, as demonstrated in the studies carried out thus far, smart inhalers do have the potential to increase adherence to inhaled medication use through AVRF and by providing feedback to healthcare professionals. However, further large-scale studies specific to testing smart inhaler efficacy are required to provide more concrete evidence of benefits and limitations in regards to medication adherence.

**Do Smart Inhalers Increase Concordance With Prescribed Doses?**

The previously mentioned studies used devices that collected data on the time of inhaler use, but this was not explicitly analysed for publication. It is therefore unclear if the inhaler doses were taken at the times intended by the prescriber. A further important issue with assessing concordance simply as the number of doses delivered by the inhaler is when an excess number of doses of medicine is dispensed in a single day. This may be either because an individual self-medicates with more preventative treatment as they feel unwell, or because they are “dose dumping” in an endeavour to appear compliant to healthcare professionals. In the relatively early trial from Charles et al. there were 53 instances amongst 110 participants of the use of at least 10 actuations of their ICS in 1 day, with a quarter of these occurring on the day of the clinic (19).

To understand the relationship between standard measures of adherence including dose use, and more recently available metrics such as doses taken within their prescribed time interval, Moran et al. (24) undertook a prospective observational study of 184 individuals with COPD. In this group, concordance with LABA-ICS as measured by dose use was 59%, but only 47% of doses were attempted within the scheduled dosing window. The same group also published a more extensive evaluation of an apparently overlapping study population (25) after hospital discharge. In this study, the average adherence (dose use) was higher but was again more than 10% greater than if the dose timing was taken into account.

The same INHaler Compliance Assessment (INCA) devices were used to establish if feedback could improve true concordance in severe asthma to a greater extent than intensive educational support (26). After 3 months of follow-up, those receiving smart inhaler feedback took more doses from their inhaler, but significantly fewer were in the prescribed dosing window (73 vs. 82%, p = 0.01). Once again, further large-scale studies are required to more accurately evaluate the relationship between smart inhalers and concordance with prescribed doses.

**Do Smart Devices Increase Inhaler Competence?**

Advances in smart inhaler technology allow feedback to users on their inhaler technique with some devices. This allows the calculation of a true level of adherence (dose taken at the right time in the right manner). This value is well below those that might be recorded by medicine possession ratio or dose counting. For example, in the study of patients with post-discharge COPD, only 6% of individuals had >80% actual concordance with their LABA-ICS. Similar results have been found in mixed populations of Airways disease (27).

In the study by Sulaiman et al. (26), smart inhaler feedback was found to be superior to intensive education in terms of the proportion of doses taken appropriately and on time (73 vs. 63%) due to lower rates of missed doses, technique errors, and overdoses. Hence, as demonstrated, smart devices have the potential to markedly improve inhaler competence. However, significantly more multicentre studies are required to demonstrate this on a larger scale and therefore influence clinical practice.

**Do Smart Devices Improve the Deployment of Action Plans?**

Smart devices hold great promise as part of a system to automate asthma and COPD action plans, improving the speed and appropriateness of escalation of care for these conditions, and thus potentially reducing the occurrence of serious harm (28). Although promising multicentre research is being undertaken to produce this type of comprehensive solution (29), we are aware that no study was published which specifically addressed this review question. Future studies addressing this question will be vital in shedding light on the relationship between smart devices and effective action plan deployment.

**DISCUSSION**

Low concordance with inhaled medication use, timing, and technique has long been recognised to be one of the major obstacles in reducing harm from asthma and COPD in higher-income countries. Despite the tremendous potential impact of “smart-inhalers” on this aspect of Airways disease management, a small volume of research studies has been undertaken in this area. In a large proportion of the studies that involve smart inhalers and particularly those with large sample sizes [e.g., the trials of as needed budesonide-formoterol (30)], the devices are deployed to measure the use and effect of a therapeutic intervention rather than being systematically studied in their own right.

Although the number of publications in this area is limited, in this review we highlighted that there appears to be robust evidence that the use of smart inhalers is associated with a substantial increase in the number of doses or preventer inhaler taken. This effect has been seen in paediatric and adult
populations, in primary and secondary care, and in asthma and COPD. If an increase in concordance of the magnitude seen in these studies were replicated on a population level, it would be sufficient to have a major impact on serious adverse outcomes such as asthma deaths (31).

Smart inhalers also have clear potential in improving true concordance with prescribed therapy. However, data in this area are currently limited to one device type and thus further work is required to establish generalisability of these promising initial study findings. In the longer term, connected devices are likely to facilitate adherence to medical advice including action plans, though data are lacking in this area at present. These are central issues, but by no means the only research questions that remain outstanding in relation to smart inhalers. The acceptability of devices to users, the environmental impact of such a high volume production of disposable electronics, and the impact of the current lack of interoperability of systems also require systematic investigation.

Given the available randomised trial evidence, it is notable that smart inhaler use is not more clearly recommended in widely used guidance for asthma and COPD. For example, the latest GINA guidelines (5) make many “Grade D” recommendations based on the experience of the authors, but simply suggest smart inhaler use as an example of a potentially successful strategy to improve adherence.

The use of smart inhalers with dose reminders and feedback has a limited but supportive evidence base in relation to concordance with preventative therapy. A clearer focus on reducing harm will hopefully see further studies in this area and also being funded, and more thorough consideration in guidelines of the Airways disease.

AUTHOR CONTRIBUTIONS
JB had the idea for the structure of the review. JB and CZ undertook literature searches, collated relevant publications, and contributed to writing the manuscript. All authors contributed to the article and approved the submitted version.

ACKNOWLEDGMENTS
The authors are grateful to colleagues at Asthma UK and in the Respiratory Effectiveness Group for providing informative discussions in this area.

REFERENCES
1. Asthma. Asthma. Canberra, ACT: Australian Institute of Health and Welfare (2020).
2. Chronic Obstructive Pulmonary Disease. Canberra, ACT: Chronic Obstructive Pulmonary Disease (2020).
3. Asthma. World Health Organisation (2021). Available online at: www.who.int/news-room/fact-sheets/detail/asthma
4. Chronic obstructive pulmonary disease (COPD). Chronic Obstructive Pulmonary Disease (COPD). World Health Organisation (2021). Available online at: www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)
5. Global Strategy for Asthma Management and Prevention. GINA: Interim Guidance About COVID-19 & Asthma. Global Initiative for Asthma (2020). Available online at: www.ginasthma.org
6. McDonald V, Hiles S, Jones KA, Clark VL, Yorke J. Health related quality of life burden in severe asthma. Med J Aust. (2018) 209:S28–33. doi: 10.5694/mjaj.1800207
7. Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and Link to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. (2014) 24:14009. doi: 10.1038/npjcppr.2014.9
8. Mukherjee M, Stoddart A, Gupta RP, Nwaru BI, Farr A, Heaven M, et al. The epidemiology, healthcare and societal burden of asthma in the UK and its member nations: analyses of standalone and linked national databases. BMC Med. (2016) 14:113. doi: 10.1186/s12916-016-0657-8
9. Patel JG NS, Dalal AA. Indirect costs in chronic obstructive pulmonary disease: a review of the economic burden on employers and individuals in the United States. Int J Chron Obstruct Pulm Dis. (2014) 19:289–300. doi: 10.2147/COPD.S7157
10. Price DB, Román-Rodríguez M, McQueen RB, Bosnic-Anticevich S, Carter V, Gruffydd-Jones K, et al. Inhaler errors in the CRITIKAL Study: type, frequency, and association with asthma outcomes. J Allergy Clin Immunol Pract. (2017) 5:1071–81. doi: 10.1016/j.jaip.2017.01.004
11. Usmani OS I, Marshall J, Dunlop WCN, Heron L, Farrington E, Dekhuijzen R. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respir Res. (2018) 19:10. doi: 10.1186/s12931-017-0710-y
12. Vrijens B, Dima AL, Van Ganse E, van Boven JF, Eakin MN, Foster JM, et al. What we mean when we talk about adherence in respiratory medicine. J Allergy Clin Immunol Pract. (2016) 4:302–12. doi: 10.1016/j.jaip.2016.05.019
13. Dima AL, Hernandez G, Cunillera O, Ferrer M, de Bruin M. Asthma inhaler adherence determinants in adults: systematic review of observational data. Eur Respir J. (2015) 45:994–1018. doi: 10.1183/09031936.00172114
14. Price D, Bosnic-Anticevich S, Briggs A, Chrystyn H, Rand C, Scheuch G, et al. Inhaler competence in asthma: common errors, barriers to use and recommended solutions. Resp Med. (2013) 107:37–46. doi: 10.1016/j.rmed.2012.09.017
15. NHS Grampian Complete the Cycle project. Don’t Waste a Breath. Available online at: www.dontwasteabreath.com/view/facts (accessed November 20, 2020).
16. Taskin DP, Rand C, Nides M, Simmons M, Wise R, Coulson AH, et al. A nebuliser chronolog to monitor compliance with inhaler use. Am J Med. (1991) 91:338–345. doi: 10.1016/0002-9343(91)90260-5
17. Costello RW, Dima AL, Ryan D, McIlvor RA, Boycott K, Chisholm A, et al. Effective deployment of technology-supported management of chronic respiratory conditions: a call for stakeholder engagement. Pragmat Obs Res. (2017) 8:119–28. doi: 10.2147/POR.S132316
18. Blakey JD, Brown M, Pinchin J, Harley M, Sharples S. Confronting resistance to rule-based medicine is essential to improving outcomes. Thorax. (2015) 70:110–1. doi: 10.1136/thoraxjnl-2014-205986
19. Charles T, Quinn D, Weatherall M, Aldington S, Beasley R, Holt S. An audiovisual reminder function improves adherence with inhaled corticosteroid therapy in asthma. J Allergy Clin Immunol. (2007) 119:811–6. doi: 10.1016/j.jaci.2006.11.700
20. Chan AH, Stewart AW, Harrison J, Camargo CA Jr, Black PN, Mitchell EA. The effect of an electronic monitoring device with audiovisual reminder function on adherence to inhaled corticosteroids and school attendance in children with asthma: a randomised controlled trial. Lancet Respir Med. (2015) 3:210–9. doi: 10.1016/S2213-2600(15)00088-9
21. Burgess SW, Sly PD, Devadason SG. Providing feedback on adherence increases use of preventive medication by asthmatic children. J Asthma. (2010) 47:198–201. doi: 10.3109/0277090909033483840
22. Morton RW, Elphick HE, Rigby AS, Daw WJ, King DA, Smith LJ, et al. STAAR: a randomised controlled trial of electronic adherence monitoring
with reminder alarms and feedback to improve clinical outcomes for children with asthma. *Thorax*. (2017) 72:347–54. doi: 10.1136/thoraxjnl-2015-208171

23. Foster JM, Usherwood T, Smith L, Sawyer SH, Xuan W, Rand CS, et al. Inhaler reminders improve adherence with controller treatment in primary care patients with asthma. *J Allergy Clin Immunol*. (2014) 134:1266–8. doi: 10.1016/j.jaci.2014.05.041

24. Moran C, Doyle F, Sulaiman I, Bennett K, Greene G, Molloy GJ, et al. The INCA(TM) (inhaled compliance assessment(TM)): a comparison with established measures of adherence. *Psychol Health*. (2017) 32:1266–87. doi: 10.1080/08870446.2017.1290243

25. Sulaiman I, Cushen B, Greene G, Sehult J, Seow D, Rawat F, et al. Objective assessment of adherence to inhalers by patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. (2017) 195:1333–43. doi: 10.1164/rccm.201604-0733OC

26. Sulaiman I, Greene G, MacHale E, Sehult J, Mokoka M, D'Arcy S, et al. A randomised clinical trial of feedback on inhaler adherence and technique in patients with severe uncontrolled asthma. *Eur Respir J*. (2018) 51:1701126. doi: 10.1183/13993003.01126-2017

27. Hess D, Nabhani Gebara S, Greene G, Co Stello RW, Kayyali R. A quantitative evaluation of adherence and inhalation technique among respiratory patients: an observational study using an electronic inhaler assessment device. *Int J Clin Pract*. (2020) 74:13437. doi: 10.1111/i tcp.13437

28. Asthma UK. *Smart Asthma: Real-World Implementation of Connected Devices in the UK to Reduce Asthma Attacks*. London (2017). Available online at: https://www.asthma.org.uk/smartasthma/ (accessed November 24, 2020).

29. Khussial RJ, Honkoop PJ, Usmani O, Soares M, Simpson A, Biddiscombe M, et al. Effectiveness of myAirCoach: a mHealth self-management system in asthma. *J Allergy Clin Immunol Pract*. (2020) 8:1972–9.e8. doi: 10.1016/j.jaip.2020.02.018

30. O’Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. *N Engl J Med*. (2018) 378:1865–76. doi: 10.1056/NEJMoa1715274

31. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. *N Engl J Med*. (2000) 343:332–6. doi: 10.1056/NEJM200008033430504

Conflict of Interest: In the last 3 years, JB has undertaken educational presentations and advisory boards for companies that manufacture inhaled medicines, with fees going to charitable accounts (Astra Zeneca, Boehringer Ingelheim, Chiesi, GSK). He has benefitted from travel and accommodation relating to conference and educational meeting attendance (Boehringer Ingelheim, GSK). He has investigator initiated grants or involvement in research collaborations with “in kind” benefit (GSK, Novartis, Teva).

The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Zabczyk and Blakey. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.